A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Pfizer

Status and phase

Terminated

Phase 3

Conditions

Hyperlipidemia

Dyslipidemia

Treatments

Drug: torcetrapib/atorvastatin

Drug: ezetimibe/simvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00267267

A5091035

Details and patient eligibility

About

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.

Full description

For additional information please call: 1-800-718-1021

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Specific LDL-C levels based on CHD risk after a six-week washout period.

Exclusion criteria

Women who are pregnant or lactating, or planning to become pregnant.
Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
Subjects requiring systemic steroids
Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.